Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.60
SVA's Cash to Debt is ranked higher than
59% of the 1233 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. SVA: 1.60 )
SVA' s 10-Year Cash to Debt Range
Min: 0.48   Max: No Debt
Current: 1.6

Equity to Asset 0.52
SVA's Equity to Asset is ranked higher than
65% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SVA: 0.52 )
SVA' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.64
Current: 0.52

0.41
0.64
Interest Coverage 2.89
SVA's Interest Coverage is ranked lower than
52% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SVA: 2.89 )
SVA' s 10-Year Interest Coverage Range
Min: 1.38   Max: 9999.99
Current: 2.89

1.38
9999.99
F-Score: 6
Z-Score: 2.27
M-Score: 1.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 6.64
SVA's Operating margin (%) is ranked higher than
87% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -80.68 vs. SVA: 6.64 )
SVA' s 10-Year Operating margin (%) Range
Min: -35600   Max: 48.44
Current: 6.64

-35600
48.44
Net-margin (%) 5.58
SVA's Net-margin (%) is ranked higher than
87% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. SVA: 5.58 )
SVA' s 10-Year Net-margin (%) Range
Min: -39700   Max: 23.7
Current: 5.58

-39700
23.7
ROE (%) 2.92
SVA's ROE (%) is ranked higher than
88% of the 1124 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. SVA: 2.92 )
SVA' s 10-Year ROE (%) Range
Min: -49.8   Max: 33.16
Current: 2.92

-49.8
33.16
ROA (%) 1.56
SVA's ROA (%) is ranked higher than
88% of the 1231 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. SVA: 1.56 )
SVA' s 10-Year ROA (%) Range
Min: -310.16   Max: 17.53
Current: 1.56

-310.16
17.53
ROC (Joel Greenblatt) (%) 4.52
SVA's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 1204 Companies
in the Global Biotechnology industry.

( Industry Median: -480.34 vs. SVA: 4.52 )
SVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1736.59   Max: 132.79
Current: 4.52

-1736.59
132.79
Revenue Growth (%) 27.30
SVA's Revenue Growth (%) is ranked higher than
92% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. SVA: 27.30 )
SVA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 81.7
Current: 27.3

0
81.7
» SVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SVA Guru Trades in Q4 2013

Jim Simons 1,054,996 sh (+17.67%)
Chris Davis 1,178,606 sh (-20%)
» More
Q1 2014

SVA Guru Trades in Q1 2014

Chris Davis 1,244,206 sh (+5.57%)
Jim Simons 1,031,711 sh (-2.21%)
» More
Q2 2014

SVA Guru Trades in Q2 2014

Jim Simons 1,175,000 sh (+13.89%)
Chris Davis 1,250,546 sh (+0.51%)
» More
Q3 2014

SVA Guru Trades in Q3 2014

Jim Simons 1,266,000 sh (+7.74%)
Chris Davis Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Chris Davis 2014-09-30 Sold Out 0.02%$4.57 - $6.01 $ 5.05-6%0
Chris Davis 2013-09-30 Reduce -43.92%0.01%$3.86 - $6.24 $ 5.056%1473343
Chris Davis 2013-03-31 New Buy0.02%$3.07 - $3.77 $ 5.0549%2627231
Chris Davis 2012-12-31 Sold Out 0.02%$2.44 - $3.46 $ 5.0578%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 48.60
SVA's P/E(ttm) is ranked higher than
91% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 48.60 )
SVA' s 10-Year P/E(ttm) Range
Min: 5.44   Max: 161.43
Current: 48.6

5.44
161.43
P/B 2.25
SVA's P/B is ranked higher than
88% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 5.68 vs. SVA: 2.25 )
SVA' s 10-Year P/B Range
Min: 0.73   Max: 11.83
Current: 2.25

0.73
11.83
P/S 4.29
SVA's P/S is ranked higher than
91% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 32.77 vs. SVA: 4.29 )
SVA' s 10-Year P/S Range
Min: 0.98   Max: 26.4
Current: 4.29

0.98
26.4
EV-to-EBIT 59.55
SVA's EV-to-EBIT is ranked higher than
90% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 59.55 )
SVA' s 10-Year EV-to-EBIT Range
Min: -1028.5   Max: 65.2
Current: 59.55

-1028.5
65.2
Shiller P/E 127.51
SVA's Shiller P/E is ranked higher than
94% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 127.51 )
SVA' s 10-Year Shiller P/E Range
Min: 15.09   Max: 182
Current: 127.51

15.09
182
Current Ratio 2.19
SVA's Current Ratio is ranked higher than
61% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. SVA: 2.19 )
SVA' s 10-Year Current Ratio Range
Min: 1.16   Max: 6.15
Current: 2.19

1.16
6.15
Quick Ratio 1.93
SVA's Quick Ratio is ranked higher than
62% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. SVA: 1.93 )
SVA' s 10-Year Quick Ratio Range
Min: 0.85   Max: 5.43
Current: 1.93

0.85
5.43

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 15.78
SVA's Price/Net Current Asset Value is ranked higher than
79% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 37.29 vs. SVA: 15.78 )
SVA' s 10-Year Price/Net Current Asset Value Range
Min: 3.37   Max: 109
Current: 15.78

3.37
109
Price/Tangible Book 2.27
SVA's Price/Tangible Book is ranked higher than
91% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. SVA: 2.27 )
SVA' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 14.04
Current: 2.27

0.9
14.04
Price/DCF (Projected) 8.56
SVA's Price/DCF (Projected) is ranked higher than
93% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 8.56 )
SVA' s 10-Year Price/DCF (Projected) Range
Min: 1.03   Max: 8.05
Current: 8.56

1.03
8.05
Price/Median PS Value 0.96
SVA's Price/Median PS Value is ranked higher than
88% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. SVA: 0.96 )
SVA' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 4.3
Current: 0.96

0.29
4.3
Price/Graham Number 2.13
SVA's Price/Graham Number is ranked higher than
96% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 2.13 )
SVA' s 10-Year Price/Graham Number Range
Min: 0.51   Max: 22.54
Current: 2.13

0.51
22.54
Earnings Yield (Greenblatt) 1.70
SVA's Earnings Yield (Greenblatt) is ranked higher than
90% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. SVA: 1.70 )
SVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 52.1
Current: 1.7

1.5
52.1
Forward Rate of Return (Yacktman) 0.69
SVA's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -6.43 vs. SVA: 0.69 )
SVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.3   Max: 9.2
Current: 0.69

-7.3
9.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SVQ.Germany
Sinovac Biotech Ltd, formerly known as Net-Force System Inc., was incorporated in Antigua and Barbuda on March 1, 1999. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company is engaged in the development, manufacturing and sales of vaccines for infectious diseases. Its product consist of Healive, for the treatment of Hepatitis A; Bilive, for the treatment of Hepatitis A&B; Anflu, for the treatment of Influenza; Panflu Whole Viron Pandemic Influenza Vaccine, for Pandemic Influenza Virus; Split Viron Pandemic Influenza Vaccine, for the treatment of Pandemic Influenza Virus; Panflu.1, for the treatment of Influenza A H1N1 virus; RabEnd, for the treatment of Rabies Virus in animals; Mumps Vaccine, for the treatment of mumps; EV71 Vaccine, Pneumococcal Polysaccharide Vaccine, Varicella Vaccine, for the treatment of varicella-zoster virus, H7N9 Vaccine, for the treatment of H7N9 influenza. The Company has four manufacturing bases located in Haidian and Changping Districts of Beijing, Dalian City of Liaoning Province, and Tangshan City of Hebei Province and also has two upstream production facilities in Haidian District, Beijing. It has built a new production site in in Changping District, Beijing, which comprises a new filing and packaging line that complies with the new PRC GMP standards, EV71 production facilities and a warehouse. The Company relies on its sales force to sell its products directly to CDCs in the private market. As of December 31, 2013, the in-house sales and marketing team consisted of 170 staff members located in 31 provinces throughout China. The Company obtains the raw materials from local and overseas suppliers. It maintains two suppliers for each key raw material, with the exception of hepatitis B antigens for Bilive production. The hepatitis B antigens are sourced from Beijing Temple of Heaven. The Company competes with Kunming Institute of Biological Product, Pukang Biological Co., Ltd., Changchun Institute of Biological Products and Changchun Changsheng Life Sciences Ltd for hepatitis A vaccine. It competes with Hualan Biological Engineering Inc., Changchun Institute of Biological Products, GSK, Aleph Biological Co., Ltd. and Zhejiang Tianyuan for influenza vaccines. The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.
» More Articles for SVA

Headlines

Articles On GuruFocus.com
Simavita Expands Board of Directors by Appointing Craig Holland and Adds Appointment to Upcoming Sha Nov 14 2014 
Sernova Provides Corporate Update Nov 10 2014 

More From Other Websites
Sinovac Reports Unaudited Third Quarter Financial Result... Nov 15 2014
Sinovac posts 3Q profit Nov 14 2014
Sinovac posts 3Q profit Nov 14 2014
Sinovac Reports Unaudited Third Quarter Financial Results Nov 14 2014
Sinovac to Host Conference Call to Report Third Quarter... Nov 05 2014
Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results Nov 05 2014
Sinovac to Participate in Jefferies 4th Annual Asia Summ... Oct 22 2014
Sinovac to Participate in Jefferies 4th Annual Asia Summit Oct 21 2014
Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference Sep 05 2014
Sinovac to Participate in Upcoming Investor Conferences Sep 02 2014
Sinovac Announces Results of 2014 Annual General Meeting of Shareholders Aug 27 2014
Sinovac Reports Unaudited Second Quarter Financial Results Aug 14 2014
Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results Jul 25 2014
Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu Jul 23 2014
Sinovac Biotech receives tender to supply Healive in Beijing under EPI Jul 21 2014
Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded... Jul 21 2014
Sinovac Schedules 2014 Annual Meeting of Shareholders Jul 14 2014
Sinovac Announces Favorable Reduction in Value Added Tax Rate Jun 25 2014
Sinovac Biotech's (SVA) CEO Weidong Yin on Q1 2014 Results - Earnings Call Transcript May 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK